SCHEMBL4345285

SCHEMBL4345285

CC(C)(c1ccc(OC(=O)O)cc1)c1cccc(C(C)(C)c2ccc(OC(=O)O)cc2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 2/20 0.55
ESR2 Q92731 2/20 0.55
TDP1 Q9NUW8 2/20 0.46
MAPT P10636 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
KDM4E B2RXH2 8/20 0.46
POLB P06746 2/20 0.46
ALDH1A1 P00352 6/20 0.45
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
LMNA P02545 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
HTT P42858 1/20 0.44
CYP3A4 P08684 1/20 0.44
RAB9A P51151 2/20 0.43
NPC1 O15118 1/20 0.43
ELANE P08246 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
CNR1 P21554 1/20 0.41
CNR2 P34972 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1031672 0.91 TDP1 (0.54) ESR1ESR2TDP1MAPTL3MBTL1
SCHEMBL10624763 0.90 ESR1 (0.55) ESR1ESR2TDP1MAPTL3MBTL1
SCHEMBL8905305 0.89 MAPT (0.50) ESR1ESR2TDP1MAPTL3MBTL1
SCHEMBL4346502 0.89 MAPT (0.50) ESR1ESR2TDP1MAPTL3MBTL1
SCHEMBL14287528 0.85 ESR1 (0.50) ESR1ESR2TDP1MAPTL3MBTL1
SCHEMBL10032079 0.84 ESR1 (0.49) ESR1ESR2TDP1MAPTKDM4E
SCHEMBL20717654 0.84 ESR1 (0.62) ESR1ESR2KDM4EPOLBALDH1A1
SCHEMBL24385840 0.84 MAPT (0.59) TDP1MAPTL3MBTL1KDM4EPOLB
SCHEMBL13526085 0.83 CYP3A4 (0.57) ESR1ESR2TDP1MAPTKDM4E
SCHEMBL2335333 0.82 ELANE (0.59) ESR1ESR2TDP1MAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090281291-A1 IMAGING MEMBERS XEROX CORPORATION (US) 2009-11-12 US disclosed
US-20060286469-A1 Imaging members XEROX CORPORATION 2006-12-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060286469-A1 Imaging members VCL, MAP1LC3C, MAP1LC3B ESR1 2083/4885ESR2 2138/4885TDP1 3816/4885
US-20090281291-A1 IMAGING MEMBERS VCL, MAP1LC3C, MAP1LC3B ESR1 2083/4885ESR2 2138/4885TDP1 3816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.